Does BPC-157 Actually Work? What the Evidence Shows - and Where It Runs Out

Last Updated: August 2026

BPC-157 occupies an unusual position: it has one of the largest preclinical bodies of work of any research peptide, and almost no human data. Both statements are true at once, and most coverage tells you only one of them.

This article goes to the primary literature instead of restating either version. What follows is where the evidence actually comes from, what the animal work shows and what it doesn't, the three human studies that exist in full detail, the registered trial that disappeared, what the July 2026 FDA vote did and did not do, and which of the widely repeated claims survive a sequence check.

Where the evidence comes from — and why that matters

A PubMed search for Predrag Sikirić as author combined with "BPC 157" returns 175 records. That is a remarkable output for a single compound, and it is also the central caveat: the overwhelming majority of BPC-157 research comes from one group, the Department of Pharmacology at the University of Zagreb, where the peptide was characterised in the 1990s.

Single-source concentration is not disqualifying. Plenty of legitimate compounds began this way. But it changes how the corpus should be read, because the usual correction mechanism — independent groups attempting to reproduce a finding and publishing when they fail — has largely not operated here.

Two 2025 reviews illustrate the split cleanly. The Zagreb group's own synthesis, "Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key" (Pharmaceuticals), states that BPC-157 "controls angiogenesis and the NO-system's healing functions" and claims "high safety (LD1 not achieved)." An independent Polish review published months earlier in the same journal, "Multifunctionality and Possible Medical Application of the BPC 157 Peptide", concluded that BPC-157 "has not been approved for use in standard medicine by the FDA and other global regulatory authorities due to the absence of sufficient and comprehensive clinical studies," and noted that "not all studies conducted on animals can always be freely transferred to humans." The Zagreb group published a formal rebuttal to it.

That disagreement, in print, between the originating group and independent reviewers is the honest state of the field.

What the molecule is

BPC-157 is a partial sequence of Body Protection Compound, a protein isolated from gastric juice. The phrase "stable gastric pentadecapeptide" that runs through the literature refers to its resistance to degradation in stomach acid — not to shelf stability in a vial, which is a separate question nobody has published on.

Keep that sequence visible. It resolves a claim further down that a great deal of storage advice rests on.

What the animal work actually demonstrates

The preclinical record is broad and, within its limits, consistent. The proposed mechanism is multi-pathway rather than single-receptor: BPC-157 has no identified dedicated receptor, and its effects are attributed to angiogenesis, the nitric oxide system, and growth factor signalling. The 2025 independent scoping review "Regeneration or Risk?" (Current Reviews in Musculoskeletal Medicine) describes activation of "VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis, promoting angiogenesis, fibroblast activity, and neuromuscular stabilization," plus ERK1/2 signalling.

Two studies are worth reading directly rather than through summaries.

In cultured rat Achilles tendon fibroblasts, BPC-157 increased growth hormone receptor expression, and adding growth hormone to treated cells produced dose- and time-dependent proliferation (Molecules, 2014). The authors concluded this "may potentiate the proliferation-promoting effect of growth hormone and contribute to the healing of tendon." That is a mechanism proposal from cell culture, and it is frequently cited as though it were a tendon-healing result.

In a rat medial collateral ligament transection model with 90-day follow-up, BPC-157 given intraperitoneally at 10 µg or 10 ng/kg, applied locally, or given orally produced "consistent functional, biomechanical, macroscopic and histological healing improvements" (Journal of Orthopaedic Research, 2010). This is a well-conducted animal study, and it is the strongest single piece of tendon-and-ligament evidence in the corpus.

The most rigorous accounting of the whole literature is the 2025 systematic review in HSS Journal, "Emerging Use of BPC-157 in Orthopaedic Sports Medicine". Its authors screened 544 articles and included 36 — of which 35 were preclinical and one was clinical. Their own limitations paragraph describes the base as "level IV and level V studies."

The human record, in full

There are three published human studies of BPC-157. Together they involve about 31 subjects. All three appeared in the same journal, and all three share the same lead author.

None is randomised. None has a control or placebo arm. None is blinded. Outcomes were captured by telephone follow-up or a global assessment score rather than a validated instrument — the design most vulnerable to expectation effects, in conditions where placebo response rates are high. The intravenous study, routinely described as establishing safety and pharmacokinetics, enrolled two people who had both used BPC-157 previously, observed them for three days, and reported no pharmacokinetic curve.

It is also worth noting a discrepancy between sources: the HSS systematic review characterises the knee study as "7 of 12 patients reported relief for >6 months," while the primary paper reports 11 of 12 with "significant improvement." Those are different endpoints — durability versus any improvement — and the gap illustrates how quickly a modest finding drifts when it is passed along.

No human trial has studied oral BPC-157. Every documented human route is parenteral or local: intra-articular, intravesical, intravenous. The oral evidence is entirely rodent.

The trial that vanished

One registered clinical trial of BPC-157 exists. NCT02637284 is a Phase 1 study of PCO-02 (Bepecin) in healthy volunteers, sponsored by PharmaCotherapia d.o.o., with an estimated enrolment of 42. It began in October 2015 with primary completion estimated for February 2016.

Its status is Unknown, last recorded as active and not recruiting. No results have been posted. No publication has appeared. A decade on, the independent Polish review refers to it as an "abandoned Phase I trial."

This matters more than its size suggests. A completed and published Phase 1 would have given the field human pharmacokinetics — absorption, half-life, dose proportionality — which remains the largest single gap in the BPC-157 evidence base. Every dosing protocol in circulation is built on rodent data and community convention because that trial never reported.

What the July 2026 FDA vote did and didn't do

This is the most misread item in current BPC-157 coverage, so it's worth stating precisely.

BPC-157 was removed from the FDA's 503A Category 2 "do not compound" list in April 2026. At the Pharmacy Compounding Advisory Committee meeting of July 23–24, 2026, the committee voted 8–6 with one abstention to recommend BPC-157 for inclusion on the 503A bulks list.

That vote is advisory and non-binding. FDA must complete formal rulemaking before anything is added to the list, a process projected for 2027 or later, and the agency is not required to follow the committee's recommendation. Nothing has been added. Compounding BPC-157 is not authorised by that vote.

BPC-157 remains prohibited at all times on the WADA Prohibited List under S0 (Non-Approved Substances), and appears on the Department of Defense prohibited ingredients list. The DoD's Operation Supplement Safety puts it plainly: BPC-157 "is not a dietary ingredient. It is an unapproved drug and cannot be legally prescribed or sold over the counter," and "there is little to no reliable scientific evidence to support the safety or effectiveness of BPC-157 in humans."

For the full sequence of determinations, see our FDA peptide regulation timeline.

Claims versus evidence

The methionine problem

A large amount of storage and handling advice for BPC-157 rests on the claim that the peptide is vulnerable to methionine oxidation. Read the sequence again:

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

There is no methionine. There is also no cysteine, no tryptophan and no tyrosine — none of the classically oxidation-labile residues. Any vendor page or article building a handling protocol on methionine oxidation is describing a residue this molecule does not contain. The sequence is independently confirmed in Gwyer et al. (Cell and Tissue Research, 2019) and matches the PubChem record.

What is genuinely true is less convenient: no peer-reviewed stability or storage study of BPC-157 has been published. Every shelf-life figure in circulation is vendor-derived. General handling practice still applies — see how to store peptides and does shaking damage peptides — but nobody can cite a degradation curve for this compound.

Pentadeca arginate: a compound with no literature

PDA is marketed as an arginine-salt form of BPC-157 with better stability and absorption, frequently with a "90% bioavailability" figure attached.

A PubMed search for "pentadeca arginate" returns zero results. No peer-reviewed publication establishes its identity, pharmacokinetics, bioavailability, stability advantage, or equivalence to BPC-157. Every source describing it is a vendor, clinic or telehealth page.

Two chemistry points are worth holding alongside that. An arginate salt is a counter-ion pairing, not a sequence change — it does not alter the peptide. And BPC-157's sequence contains no arginine of its own, so the name describes what has been added to the molecule, not what it is. The pentadeca arginate compound page tracks it; the evidence base for the differentiating claims is currently empty.

What you can actually verify before buying

Since the clinical questions are unresolved, the questions you can answer are about the vial in front of you.

Purity and quantity are separate axes — a 99% pure vial can be substantially underfilled, which is why net peptide content deserves as much attention as the purity number. The general framework is in how to verify peptide quality before you buy, and the compound-specific walkthrough in where to buy BPC-157.

There is a documented precedent for why this is not paranoia. Research-grade custom peptides from two independent commercial suppliers were found to carry contaminating peptides at roughly 1% by weight — enough to produce false-positive results in immunology assays, with a correlation of r²=0.90 between responses to the contaminated peptide and to the contaminant (Clinical and Vaccine Immunology, 2008). That study concerned HIV vaccine peptide libraries rather than BPC-157, but it establishes that reputable suppliers ship contaminated material at levels that change outcomes.

What independent testing shows

Peptigrity's Purity Index records a BPC-157 purity index of 99.37 across 588 recency-weighted tests from 23 laboratories (verified August 2026), against a platform composite of 99.50. The compound page shows 805 total HPLC tests averaging 99.35% across 230 verified shops — the larger figure because the index applies recency weighting and excludes blend vials and net-content-only tests.

Both carry the same caveat: these are certificates vendors chose to publish, which is a selection-biased sample rather than a random market survey. It is still the largest analytical dataset on BPC-157 that exists — there is no published product-testing study to compare it against.

On price, BPC-157 price data shows 66 shops in stock, a median of $5.90/mg and a lowest tracked price of $1.50/mg on a 10 mg vial (verified August 2026). Those figures exclude shipping, taxes and customs, coupon codes and bulk tiers, multi-vial kits, and vendors requiring an account to display a price — the lowest figure is the lowest of tracked sources, not the lowest payable.

The trial that would settle this

Everything above points at the same missing object: a properly designed human trial. It is worth spelling out what one would need to look like, because it clarifies how far the current evidence sits from an answer.

Until something like that reports, the independent reviewers' conclusion stands. As the 2025 Current Reviews in Musculoskeletal Medicine scoping review put it: "Until well-designed clinical trials are conducted, BPC-157 should be considered investigational, and its use approached with caution."

Frequently Asked Questions

Does BPC-157 work?

In animals, consistently and across many tissue types. In humans, nobody knows — the entire human record is three uncontrolled pilot studies totalling about 31 subjects, with no randomised trial of any indication.

Is BPC-157 legal now that the FDA advisory committee backed it?

No. The July 2026 vote was a non-binding recommendation. FDA must complete rulemaking before BPC-157 could be legally compounded, projected for 2027 or later. It remains an unapproved drug and is prohibited in sport at all times under WADA's S0 category.

Does oral BPC-157 work?

No human study has tested it. Rodent studies show oral dosing produces effects, and the peptide is genuinely acid-stable — but stability in the stomach is not the same as absorption into circulation. See BPC-157 oral vs injectable.

Does BPC-157 cause cancer?

There is no evidence that it does and no evidence that it doesn't. The theoretical concern follows from the mechanism: a compound that promotes new blood vessel formation warrants caution in anyone with an existing or suspected malignancy, because that is also how tumours grow. No human study has examined it.

Do I need to worry about oxidation when storing it?

Not for the reason usually given — BPC-157 contains no methionine, cysteine, tryptophan or tyrosine. Handle it as you would any lyophilised peptide, but be aware that no published stability study for this compound exists.

How do I know the vial is really BPC-157?

Mass spectrometry showing a mass near 1419.5 Da. HPLC purity alone cannot confirm identity — it only tells you what proportion of the contents is a single species, not which species it is.

Where this sits

BPC-157 is a compound with unusually strong animal data, an unusually weak human record, and an unusually concentrated authorship. That combination is worth taking seriously in both directions: it is neither the settled healing agent its promoters describe nor the empty claim its harshest critics imply. It is a genuinely promising preclinical compound that has not been tested properly in people, sold in a market where the material itself is unverified by default.

Browse our complete peptide guide with 118 compounds (verified August 2026), compare shops through independent lab tests, and see what others are reporting in the community forum.

This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.